Skip to content
Home/Companies/Pharma/Cobra Biologics

Cobra Biologics

Pharma·United Kingdom·Exited 2020·Held 9yr
Entry
2011
Hold
9yr
Exit
2020

Who owns Cobra Biologics?

Cobra Biologics is a British Pharma company, now owned by Cognate BioServices, which acquired it in 2020 from Flerie.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Flerie
Investor
Flerie
Flerie Invest · 2011 · Life Sciences VC

Key facts

HQUnited Kingdom
SectorPharma
StatusAcquired
Exit Type
Trade Sale
Buyer
Cognate BioServices
Exit Year
2020

More from Flerie Invest

Other portfolio companies in the same fund.

Frontier Biosolutions
Active
PharmaGermany· 2023
Mendus
Active
BiotechSweden· 2023
A3P Biomedical
Exited 2025
BiotechSweden· 2022
Alder Therapeutics
Active
BiotechSweden· 2022
AnaCardio
Active
BiotechSweden· 2022
Bohus Biotech
Active
PharmaSweden· 2022

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns Cobra Biologics?

Cobra Biologics is now owned by Cognate BioServices, which acquired it in 2020 from Flerie.

When did Cognate BioServices acquire Cobra Biologics?

Cognate BioServices acquired Cobra Biologics in 2020, buying from Flerie.

Who did Cobra Biologics sell to?

Flerie sold Cobra Biologics to Cognate BioServices in 2020 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue